SOX2 and non-small cell lung carcinoma: Basically, the presence of SOX2-specific T cells (Dhodapkar et al., 2013) and humoral immune responses against SOX2 had been identified in the patients with NSCLC and small cell lung cancer (SCLC) (Gure et al., 2000), respectively and this finding holds potential for immunotherapy targeting the SOX2-expressing tumors.